Single-Dose Nirsevimab Prevents RSV Infection
- Shabir Madhi; Eric Simões
Access Resources
About
This article commentary discusses a study on nirsevimab, a single-dose treatment that helps prevent RSV infections in preterm infants. Conducted across 164 sites in 23 countries, the trial showed that nirsevimab reduced RSV-related lung infections and hospitalizations. It was more effective than placebo, with significant reductions in risk and fewer needed treatments to see benefits. The study highlights the lack of licensed vaccines for RSV and suggests nirsevimab as a promising option. However, concerns about viral mutations affecting its effectiveness and issues like cost may limit access for children in low-income areas.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.